DK3004896T3 - Markør for forstyrrelser i forhold til sur sphingomyelinase og anvendelser deraf - Google Patents

Markør for forstyrrelser i forhold til sur sphingomyelinase og anvendelser deraf Download PDF

Info

Publication number
DK3004896T3
DK3004896T3 DK14735056.5T DK14735056T DK3004896T3 DK 3004896 T3 DK3004896 T3 DK 3004896T3 DK 14735056 T DK14735056 T DK 14735056T DK 3004896 T3 DK3004896 T3 DK 3004896T3
Authority
DK
Denmark
Prior art keywords
surfactures
marker
applications
under acid
acid sphingomyelinase
Prior art date
Application number
DK14735056.5T
Other languages
English (en)
Inventor
Wei-Lien Chuang
Gerald F Cox
X Kate Zhang
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DK3004896T3 publication Critical patent/DK3004896T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/04Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012Sphingomyelin phosphodiesterase (3.1.4.12)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/916Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08Sphingolipids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
DK14735056.5T 2013-06-07 2014-06-06 Markør for forstyrrelser i forhold til sur sphingomyelinase og anvendelser deraf DK3004896T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361832302P 2013-06-07 2013-06-07
PCT/US2014/041405 WO2014197859A1 (en) 2013-06-07 2014-06-06 Marker for acid sphingomyelinase disorders and uses thereof

Publications (1)

Publication Number Publication Date
DK3004896T3 true DK3004896T3 (da) 2020-01-06

Family

ID=51062988

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14735056.5T DK3004896T3 (da) 2013-06-07 2014-06-06 Markør for forstyrrelser i forhold til sur sphingomyelinase og anvendelser deraf

Country Status (31)

Country Link
US (3) US10022428B2 (da)
EP (2) EP3584580A1 (da)
JP (4) JP6457501B2 (da)
KR (3) KR102228367B1 (da)
CN (2) CN105474017A (da)
AU (4) AU2014274670B2 (da)
BR (1) BR112015030099A2 (da)
CA (1) CA2914751C (da)
CL (1) CL2015003563A1 (da)
CR (1) CR20150638A (da)
DK (1) DK3004896T3 (da)
EA (1) EA035342B1 (da)
ES (1) ES2762608T3 (da)
HK (1) HK1217534A1 (da)
HR (1) HRP20192246T1 (da)
HU (1) HUE047863T2 (da)
IL (3) IL284102B2 (da)
LT (1) LT3004896T (da)
MA (1) MA38638B1 (da)
MX (1) MX370570B (da)
MY (1) MY185990A (da)
NZ (1) NZ754328A (da)
PH (1) PH12015502687A1 (da)
PL (1) PL3004896T3 (da)
PT (1) PT3004896T (da)
RS (1) RS59677B1 (da)
SG (2) SG11201509622WA (da)
SI (1) SI3004896T1 (da)
UA (1) UA120591C2 (da)
WO (1) WO2014197859A1 (da)
ZA (1) ZA201508630B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3482767T (pt) * 2009-08-28 2021-12-29 Icahn School Med Mount Sinai Terapia de substituição enzimática com escaladas de dose para tratamento de deficência da esfingomielinase ácida
EA035342B1 (ru) * 2013-06-07 2020-05-29 Джензим Корпорейшн Способы контроля лечения пациента, имеющего ассоциированное с кислой сфингомиелиназой (asm) нарушение
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病c型を予防または治療するための医薬組成物
EP3672622B1 (en) 2017-08-24 2023-11-08 Genzyme Corporation Recombinant human acid sphingomyelinase for use in treating abnormal bone conditions in acid sphingomyelinase deficiency patients
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
AU2020282831A1 (en) 2019-05-31 2021-12-16 Genzyme Corporation Two-dimensional LC-MS/MS systems
WO2024026390A2 (en) * 2022-07-28 2024-02-01 Wylder Nation Foundation Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
AR034413A1 (es) 2000-08-25 2004-02-25 Nestor Abel Chamoles Metodo para determinar la actividad de las enzimas lisosomales
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
JP2006214731A (ja) * 2005-02-01 2006-08-17 Institute Of Physical & Chemical Research スフィンゴミエリンの検出方法
EP1960534A4 (en) 2005-12-15 2009-03-25 Univ New York State Res Found ENZYMATIC METHODS FOR MEASURING THE SPHINGOMYLELIN AND PHOSPHATIDYLCHOLIN SHARE IN PLASMA AND TISSUE
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US8026099B2 (en) 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders
US8497122B2 (en) 2008-04-11 2013-07-30 Washington University Biomarkers for Niemann-pick C disease and related disorders
PT3482767T (pt) * 2009-08-28 2021-12-29 Icahn School Med Mount Sinai Terapia de substituição enzimática com escaladas de dose para tratamento de deficência da esfingomielinase ácida
JP2013002933A (ja) 2011-06-16 2013-01-07 Hitachi Plant Technologies Ltd 3次元測位システム
MX359328B (es) 2011-11-15 2018-09-25 Centogene Ag Metodo para el diagnostico de enfermedad de niemann-pick.
CA2912274A1 (en) * 2013-05-14 2014-11-20 Centogene Ag Method for the diagnosis of niemann-pick disease
EA035342B1 (ru) * 2013-06-07 2020-05-29 Джензим Корпорейшн Способы контроля лечения пациента, имеющего ассоциированное с кислой сфингомиелиназой (asm) нарушение

Also Published As

Publication number Publication date
HK1217534A1 (zh) 2017-01-13
KR102434244B1 (ko) 2022-08-19
JP6457501B2 (ja) 2019-01-23
WO2014197859A1 (en) 2014-12-11
EA201592265A1 (ru) 2016-04-29
US20160120958A1 (en) 2016-05-05
IL298675A (en) 2023-01-01
EP3584580A1 (en) 2019-12-25
JP2021075544A (ja) 2021-05-20
PH12015502687A1 (en) 2016-03-07
CR20150638A (es) 2016-02-08
RS59677B1 (sr) 2020-01-31
PT3004896T (pt) 2019-12-23
MX370570B (es) 2019-12-17
IL284102B (en) 2022-12-01
MA38638A1 (fr) 2017-02-28
JP2024038145A (ja) 2024-03-19
EP3004896B1 (en) 2019-09-18
AU2014274670A1 (en) 2016-01-07
KR20210031541A (ko) 2021-03-19
HUE047863T2 (hu) 2020-05-28
SI3004896T1 (sl) 2020-01-31
CN105474017A (zh) 2016-04-06
CA2914751A1 (en) 2014-12-11
JP2016526050A (ja) 2016-09-01
JP6835806B2 (ja) 2021-02-24
CL2015003563A1 (es) 2016-08-05
KR20160018651A (ko) 2016-02-17
US20210162021A1 (en) 2021-06-03
MA38638B1 (fr) 2018-03-30
AU2018200977B2 (en) 2020-07-23
LT3004896T (lt) 2020-01-10
US10888607B2 (en) 2021-01-12
AU2020257114B2 (en) 2023-03-16
IL284102B2 (en) 2023-04-01
AU2018200977A1 (en) 2018-03-01
ZA201508630B (en) 2020-01-29
SG10201709925SA (en) 2017-12-28
CA2914751C (en) 2023-10-03
US10022428B2 (en) 2018-07-17
NZ754328A (en) 2021-12-24
MX2015016844A (es) 2016-04-04
UA120591C2 (uk) 2020-01-10
EP3004896A1 (en) 2016-04-13
HRP20192246T1 (hr) 2020-03-06
ES2762608T3 (es) 2020-05-25
JP2019089767A (ja) 2019-06-13
MY185990A (en) 2021-06-14
AU2023201062A1 (en) 2023-03-23
NZ715001A (en) 2021-10-29
BR112015030099A2 (pt) 2017-07-25
PL3004896T3 (pl) 2020-04-30
KR102228367B1 (ko) 2021-03-16
IL242964B (en) 2021-07-29
CN115128287A (zh) 2022-09-30
AU2014274670B2 (en) 2017-11-09
US11998592B2 (en) 2024-06-04
KR20210104177A (ko) 2021-08-24
KR102292298B1 (ko) 2021-08-24
SG11201509622WA (en) 2015-12-30
IL284102A (en) 2021-07-29
EA035342B1 (ru) 2020-05-29
JP7414750B2 (ja) 2024-01-16
US20180289778A1 (en) 2018-10-11
AU2020257114A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
DK3043784T3 (da) Arylethere og anvendelser deraf
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
DK3683235T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
DK3089994T3 (da) Fabs-in-tandem-immunglobulin og anvendelser deraf
DK3027209T3 (da) Anti-Activin A-antistoffer og anvendelser deraf
DK2999103T3 (da) Konverter og fremgangsmåde til styring deraf
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
DK3004896T3 (da) Markør for forstyrrelser i forhold til sur sphingomyelinase og anvendelser deraf
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK3022361T4 (da) Rambuk og fremgangsmåde til anvendelse deraf
DK2947141T3 (da) Mikroorganismer der fremstiller docosahexaensyre og anvendelse deraf
DK3016547T3 (da) Dyrebarriere og fremgangsmåde
DK2994150T3 (da) Probiotika og fremgangsmåde til anvendelse
DK3060922T3 (da) Fremgangsmåde og anordning til proteinfremstilling
DK3083523T3 (da) Silicasammensætning og fremgangsmåde til fremstilling
DK3060225T3 (da) Leveringssystem og probiotisk sammensætning til dyr
DK2994346T3 (da) Transportvogn til stykgods
DK3072896T3 (da) Taxanforbindelse og fremgangsmåde til fremstilling heraf og dennes anvendelse